Practical Strategies to Reduce HF Hospitalizations in African American Patients.

Slides:

Advertisements

Similar presentations

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention

Introduction to Direct-to-Consumer Genetic Testing

Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.

Prior Trials of RAAS Inhibitors

Silent No More:.

Emerging Concepts in Heart Failure

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Heart Failure and Hospital Readmissions

Heart Rate, HF Admissions, and Readmissions

Patient Case Discussions in T2D: What Intensification Plan Is Best?

Unmet Needs in the Secondary Prevention in ACS

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Select Topics in Cardiovascular Medicine

How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

PrEP in Women: Unique Considerations and Strategies

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Surveying the Safety of NOACs in the Real World

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

Blood pressure control: dependence on adherence

When Would You Use Single Inhaler Triple Therapy in COPD?

T2DM and CV Outcomes Trials: A Deep Dive!

Improving Management of Type 2 Diabetes in Hispanic/Latino Patients

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.

VTE Treatment Conventional Approach

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Efficacy and Safety of Edoxaban in Patients With AF and HF

Antithrombotic Protection in CAD and HF

Expert Insights on Complex Clinical Cases of Edema

Therapeutic Strategies in COPD Focus on Patient Characteristics and Drug Delivery.

Risk Stratification in CAD and PAD

Oral Anticoagulation in AF

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Using Heart Rate as a Biomarker in Clinical Practice.

Novel Approaches to T1D Management

Anticoagulation and Thrombosis Management

Updates in Heart Failure:

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

CAD and HF Often Coexist

New Strategies to Reduce HF Readmissions

Considerations in Managing Seizures in Women

The Impact of Prior Heart Failure Hospitalizations on Long-term Mortality Differs by Baseline Risk of Death Naga V.A. Kommuri, MD, Todd M. Koelling,

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Iron Deficiency in Heart Failure

Proteasome Inhibitors and Patients

Improving Adherence to Antiplatelet Therapy After an ACS Event

Clinical Challenges and Updates in Managing Seizure Clusters

Assessing the Burden of Hyperkalemia

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Baseline Characteristics by Baseline N-BNP Level

Breaking Down the Data in Hyperkalemia

Contemporary Considerations in Biomarker-Guided Therapy

Peanut Allergy Immunotherapy

HF-Related Hospitalization and Readmissions

Strategies for Infection Control in Cystic Fibrosis

AMD Therapy: Where Are We Now and Where Are We Going?

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Assessing the Burden of Hyperkalemia

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Dennis M. McNamara et al. JCHF 2014;2:

My PAH Patient.

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Fighting MDR G-Negative Infections

RAASi Enabling in the Modern Era

Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.

Presentation transcript:

Practical Strategies to Reduce HF Hospitalizations in African American Patients

Learning Objectives

Case 76-Year-Old AA Woman

Case (cont) 76-Year-Old AA Woman

Framingham Heart Study Lifetime Risk for CHF

HF in African Americans

IMPROVE-HF: Adherence to GDMT Use in Real World Practices

Adherence to I/H Use in AA Patients

A-HeFT: FDC of I/H in AAs With HF Study Design

A-HeFT Efficacy and Safety

A-HeFT Influence of BP on Effectiveness of FDC I/H

Repeat HF Hospitalizations Predict Mortality

GRAHF: A-HeFT Genetic Substudy NOS3 Polymorphisms

GRAHF FDC I/H Treatment Effect by GNB3 Genotypes

GNB3 T825C Polymorphism

Distribution of GNB3 Genotypes by Race GRAHF and GRACE

GRAHF Baseline Characteristics by GNB3 Genotype

Case: 76-Year Old AA Woman Treatment With FDC I/H

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)